These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4675088)

  • 1. Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects.
    Heding LG; Rasmussen SM
    Diabetologia; 1972 Dec; 8(6):408-11. PubMed ID: 4675088
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.
    Czyzyk A; Heding LG; Malczewski B; Miedzinska E
    Diabetologia; 1975 Apr; 11(2):129-33. PubMed ID: 168107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
    Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
    Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose.
    Unger RH; Ohneda A; Valverde I; Eisentraut AM; Exton J
    J Clin Invest; 1968 Jan; 47(1):48-65. PubMed ID: 5638120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs.
    Vranic M; Pek S; Kawamori R
    Diabetes; 1974 Nov; 23(11):905-12. PubMed ID: 4430418
    [No Abstract]   [Full Text] [Related]  

  • 6. Insuppressibility of plasma glucagon by orally or intravenously administered glucose in diabetes mellitus.
    Kurahachi H; Seino Y; Ikeda M; Sakurai H; Yoshimi T; Imura H
    Endocrinol Jpn; 1977 Oct; 24(5):413-9. PubMed ID: 590199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma insulin levels in endocrine diseases. I. Plasma insulin levels in normal subjects and diabetic patients].
    Ikeda M
    Nihon Naibunpi Gakkai Zasshi; 1971 Aug; 47(5):282-90. PubMed ID: 5106320
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of pancreatic alpha cell function in normal and diabetic subjects.
    Unger RH; Aguilar-Parada E; Müller WA; Eisentraut AM
    J Clin Invest; 1970 Apr; 49(4):837-48. PubMed ID: 4986215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating C-peptide immunoreactivity. Studies in normals and diabetic patients.
    Block MB; Mako ME; Steiner DF; Rubenstein AH
    Diabetes; 1972 Oct; 21(10):1013-26. PubMed ID: 4116300
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance.
    Borghi VC; Wajchenberg BL; Cesar FP
    Metabolism; 1984 Dec; 33(12):1068-74. PubMed ID: 6390086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a sensitive and specific radioimmunoassay for pancreatic glucagon in human plasma and its clinical application.
    Borghi VC; Wajchenberg BL; Albuquerque RH
    Clin Chim Acta; 1984 Jan; 136(1):39-48. PubMed ID: 6692564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ketosis-resistance in fibro-calculous-pancreatic-diabetes. 1. Clinical observations and endocrine-metabolic measurements during oral glucose tolerance test.
    Yajnik CS; Shelgikar KM; Naik SS; Kanitkar SV; Orskov H; Alberti KG; Hockaday TD
    Diabetes Res Clin Pract; 1992 Feb; 15(2):149-56. PubMed ID: 1563331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady state plasma insulin response to continuous glucose infusion in normal and diabetic subjects.
    Reaven GM; Farquhar JW
    Diabetes; 1969 May; 18(5):273-9. PubMed ID: 5795851
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma glucose, insulin, pancreatic, and enteroglucagon levels in normal and depancreatized dogs.
    Matsuyama T; Foà PP
    Proc Soc Exp Biol Med; 1974 Oct; 147(1):97-102. PubMed ID: 4438349
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma glucagon-like immunoreactivity (GLI) in dogs.
    Oneda A; Horigome K; Yanbe A; Ishii S; Itabashi H
    Tohoku J Exp Med; 1975 Apr; 115(4):337-43. PubMed ID: 1145615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon and diabetes mellitus.
    Herlihy B
    Crit Care Nurse; 1983; 3(1):38-43. PubMed ID: 6402337
    [No Abstract]   [Full Text] [Related]  

  • 17. Abnormalities of glucagon metabolism in diabetes mellitus.
    Day JL; Anderson J
    Clin Endocrinol (Oxf); 1973 Jul; 2(3):211-7. PubMed ID: 4760546
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load.
    Rovira A; Garrote FJ; Pascual JM; Salvador MG; Herrera Pombo JL; Valverde I
    Diabetologia; 1985 Feb; 28(2):80-6. PubMed ID: 3838521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment.
    Matsuyama T; Hoffman WH; Dunbar JC; Foà NL; Foà PP
    Horm Metab Res; 1975 Nov; 7(6):452-6. PubMed ID: 1213649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and significance of islet-cell autoantibodies in different types of diabetes mellitus.
    Del Prete GF; Betterle C; Padovan D; Erle G; Toffolo A; Bersahi G
    Diabetes; 1977 Oct; 26(10):909-15. PubMed ID: 332567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.